Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus NICARDIPINE HYDROCHLORIDE IN 0 86 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus NICARDIPINE HYDROCHLORIDE IN 0 86 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes, leading to vasodilation and reduced myocardial contractility.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion: initial rate 5 mg/hour, titrate by 2.5 mg/hour every 15 minutes as needed up to 15 mg/hour. For acute hypertension, 5 mg/hour initial, increase by 2.5 mg/hour every 5-15 minutes to maximum 15 mg/hour.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life is 2 to 4 hours; prolonged in hepatic impairment or with continuous infusion.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 35% of metabolites.
Category C
Category A/B
Electrolyte
Electrolyte